Nathan Rice
Stock Analyst at Piper Sandler
(2.84)
# 2,423
Out of 4,876 analysts
52
Total ratings
45.45%
Success rate
8.81%
Average return
Main Sectors:
Stocks Rated by Nathan Rice
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BFC Bank First | Maintains: Neutral | $110 → $111 | $118.47 | -6.31% | 6 | Apr 17, 2025 | |
| MBIN Merchants Bancorp | Maintains: Overweight | $53 → $57 | $33.40 | +69.16% | 7 | Jan 30, 2025 | |
| FMBH First Mid Bancshares | Maintains: Overweight | $46 → $47 | $37.70 | +24.67% | 3 | Nov 1, 2024 | |
| BY Byline Bancorp | Reiterates: Overweight | $34 | $26.75 | +27.10% | 8 | Oct 29, 2024 | |
| CVS CVS Health | Maintains: Buy | $85 → $74 | $68.49 | +8.04% | 2 | May 2, 2024 | |
| NIC Nicolet Bankshares | Assumes: Neutral | $84 | $125.03 | -32.82% | 1 | Jan 10, 2024 | |
| ALGN Align Technology | Downgrades: Sell | $197 | $188.52 | +4.50% | 10 | Dec 11, 2023 | |
| ELAN Elanco Animal Health | Maintains: Sell | $11 → $9 | $14.29 | -37.02% | 1 | Apr 25, 2023 | |
| IDXX IDEXX Laboratories | Upgrades: Buy | $530 → $435 | $531.32 | -18.13% | 4 | Jul 21, 2022 | |
| CI The Cigna Group | Initiates: Neutral | $233 | $326.31 | -28.60% | 5 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $83 | $53.99 | +53.73% | 4 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $17.70 | -15.25% | 1 | Dec 19, 2019 |
Bank First
Apr 17, 2025
Maintains: Neutral
Price Target: $110 → $111
Current: $118.47
Upside: -6.31%
Merchants Bancorp
Jan 30, 2025
Maintains: Overweight
Price Target: $53 → $57
Current: $33.40
Upside: +69.16%
First Mid Bancshares
Nov 1, 2024
Maintains: Overweight
Price Target: $46 → $47
Current: $37.70
Upside: +24.67%
Byline Bancorp
Oct 29, 2024
Reiterates: Overweight
Price Target: $34
Current: $26.75
Upside: +27.10%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85 → $74
Current: $68.49
Upside: +8.04%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $125.03
Upside: -32.82%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $188.52
Upside: +4.50%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11 → $9
Current: $14.29
Upside: -37.02%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530 → $435
Current: $531.32
Upside: -18.13%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $326.31
Upside: -28.60%
Dec 14, 2021
Initiates: Neutral
Price Target: $83
Current: $53.99
Upside: +53.73%
Dec 19, 2019
Initiates: Overweight
Price Target: $15
Current: $17.70
Upside: -15.25%